Exhibit with us
*mymedicalexpo  
English
  1. Catalogs
  2. FIRALIS GROUP
  3. NeuroLINCs IVD test for brain-enriched lncRNA measurement
video corpo

NeuroLINCs IVD test for brain-enriched lncRNA measurement

NeuroLINCs IVD test for brain-enriched lncRNA measurement
1 / 4 PagesView full catalog

NeuroLINCs IVD test for brain-enriched lncRNA measurement

Product catalog summary
Introduction
NeuroLINCs is a non-invasive diagnostic test designed to measure brain-enriched and neurodegenerative disease-specific long non-coding RNAs (lncRNAs) in blood and plasma samples. It aims to aid in the diagnosis of cognitive impairments, Alzheimer's, and other neurodegenerative diseases.

Features & Benefits
  • First-of-its-kind test for measuring brain-enriched lncRNAs in peripheral blood and plasma.
  • Utilizes blood lncRNA biomarkers for diagnosing mild cognitive impairment (MCI), early Alzheimer's, and other dementia types.
  • Investigates a novel class of therapeutic targets with a proprietary list of brain-enriched lncRNAs.
  • Employs over 100,000 capture probes for comprehensive lncRNA sequence coverage.
  • Provides direct insights into brain conditions using blood samples, eliminating the need for brain biopsies.
  • Targets sequencing for quantifying 7,494 brain-enriched lncRNAs.

Application & Performance
  • The NeuroLINCs panel delivers highly reproducible results, facilitating the discovery of new biomarkers.
  • When combined with clinical data, these biomarkers enhance the performance of existing predictive models.
  • Signatures based on a subset of lncRNAs detected by the NeuroLINCs panel have been successfully used to diagnose Alzheimer's patients compared to healthy controls.

Company Information
Amoneta Diagnostics, an affiliate of Firalis, focuses on improving disease outcomes and therapeutic decisions through biomarker discovery and development. The company develops and markets research-use-only (RUO) and in vitro diagnostic (IVD) kits for neurodegenerative diseases, adhering to high-quality standards (ISO 9001, ISO 13485, ISO 17025, and NF S 96-900).

Partnerships & Support
  • Collaborations with Alzheimer Europe, Horizon2020, ADDF, and clinical centers of excellence.
  • Funding support from the ADDF Diagnostics Accelerator, in collaboration with Bill Gates and other philanthropic partners.

Services
Firalis offers a comprehensive range of services, including clinical qualification, biobanking, assay development, production facilities, testing, and data analysis, ensuring high-quality service at each step of the process.
See more

Catalog excerpts

NeuroLINCs IVD test for brain-enriched lncRNA measurement-1

Neurodegenerative LncRNA Biomarkers: Novel targets Hot topic in Research & Innovation of Tomorrow’s Medicine. Capture of 7494 brain specific lncRNAs in blood and plasma for downstream characterization by NGS of patients with cognitive impairment, Alzheimer and other Neurodegenerative Diseases

 Open the catalog to page 1
NeuroLINCs IVD test for brain-enriched lncRNA measurement-2

NeuroLINCs NeuroLINCs is a non-invasive test that measures brain-enriched and neurodegenerative disease specific long non-coding RNAs (lncRNAs), in plasma and blood samples. Targeted Sequencing for the quantification of 7494 brain enriched long non-coding RNAs. Features & Benefits First in class test for the measurement of brain enriched lncRNAs in peripheral blood & plasma. Blood lncRNA biomarkers for diagnostic of MCI, early Alzheimer & other dementia types. Investigation of a novel class of therapeutic targets. Proprietary list of brain enriched lncRNAs. More than 100.000 capture probes for...

 Open the catalog to page 2
NeuroLINCs IVD test for brain-enriched lncRNA measurement-3

NeuroLINCs Application & Performance Neurolincs panel leads to highly reproducible results that can be used to discover new biomarkers. When combined with clinical date, these biomarkers can significantly increase the performance of existing predictive models (David W. Thomas and Al, Clinical Development Success Rates 2006-2015). The performance of signature based on a subset of lncRNA detected in Neurolincs panel have been successfully applied to diagnose Alzheimer patients in comparison to healthy control (A).

 Open the catalog to page 3
NeuroLINCs IVD test for brain-enriched lncRNA measurement-4

Neurodegenerative LncRNA Biomarkers: Novel targets Hot topic in Research & Innovation of Tomorrow’s Medicine. NeuroLINCs kit can be part of a complete service Firalis offers an integrated panel of services ranging from clinical qualification, biobanking, assay development, production facilities, testing and data analysis to support you while using NeuroLINCs kit. These facilities and related services follow the highest quality standards to provided the best quality of service at each step of the process. AMONETA DIAGNOSTICS Learn More Amoneta Diagnostics, affiliate of Firalis, is a biotechnology...

 Open the catalog to page 4

All FIRALIS GROUP catalogs and technical brochures

  1. APO-Easy® (De Novo FDA-approved & CE-IVDR kit for ApoE Genotyping)
    APO-Easy® (De Novo FDA-approved & CE-IVDR kit for ApoE Genotyping)

    2  Pages

  2. NeuroDeGene® DNA-targeted sequencing panel for SNP and INDEL detection
    NeuroDeGene® DNA-targeted sequencing panel for SNP and INDEL detection

    2  Pages

  3. MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit
    MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit

    2  Pages

  4. Human Caldesmon Sandwich ELISA Kit
    Human Caldesmon Sandwich ELISA Kit

    2  Pages

  5. Human Calponin 1 Sandwich ELISA Kit
    Human Calponin 1 Sandwich ELISA Kit

    2  Pages

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.